Diagnostic value of GATA3, MGB and GCDFP-15 in breast cancer
10.3760/cma.j.issn.115807-20190925-00182
- VernacularTitle:GATA3、MGB和GCDFP-15在乳腺癌中的病理诊断价值
- Author:
Jingping YUAN
1
;
Juan WU
;
Xinxin YU
;
Hao WU
;
Honglin YAN
Author Information
1. 武汉大学人民医院病理科 430060
- From:
Chinese Journal of Endocrine Surgery
2020;14(2):94-99
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the diagnostic value of GATA binding protein 3 (GATA3) , mammaglobin (MGB) and gross cystic disease fluid protein-15 (GCDFP-15) in breast cancer.Methods:Immunohistochemistry was performed to detect the expression of GATA3, MGB, GCDFP-15, estrogen receptor (ER) , progesterone receptor (PR) , human epidermal growth factor receptor 2 (HER2) and Ki-67 in breast cancer. The breast cancer was divided into primary/metastatic breast cancer, hormone receptor positive/negative, or different molecular types of breast cancer according to the tissue origin and immunophenotype. The positive rates of GATA3, MGB and GCDFP-15 were statistically analyzed.Results:The positive rate of GATA3 in primary/metastatic breast cancer (92.5%; 94.25%) was significantly higher than that of MGB (42.11%; 29.17%) and GCDFP-15 (55.77%; 31.34%) ( P<0.01) , and GATA3 had better sensitivity for evaluating the tumor of unknown origin, especially in malignant hydrops. In addition, the positive rate of MGB and GCDFP-15 in hormone receptor negative and triple negative breast cancer was low, which further increased the difficulty of diagnosis of these two kinds of metastatic breast cancer. However, the positive rate of GATA3 in hormone receptor negative (90.38%) or triple negative breast cancer (85.29%) was significantly higher than that of MGB (20.00%; 5.00%) and GCDFP-15 (35.09%; 33.33%) ( P<0.01) , suggesting that it had great potential diagnostic value in hormone receptor negative and triple negative metastatic breast cancer and was a specific marker superior to MGB and GCDFP-15. Conclusion:GATA3 has a higher diagnostic value than MGB and GCDFP-15 for the assessment of tumors of unknown origin, especially in malignant hydrops, or breast cancer with an immunophenotype of hormone receptor negative and triple negative breast cancer.
